GLP-1 Supplements & Nutrient Support

Last reviewed: May 27, 2026

Last updated: May 27, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists slow gastric emptying and reduce caloric intake, which may compromise absorption of essential micronutrients including B12, folate, calcium, and iron. Research indicates 10-30% of GLP-1 users develop subclinical vitamin deficiencies within 6-12 months of continuous therapy.

Supplementation during GLP-1 treatment is not a one-size-fits-all decision. PlexusDx supports precision supplementation by combining baseline biomarker assessment with genetic predisposition screening, enabling providers to recommend nutrients aligned with individual absorption patterns and medication interactions rather than generic protocols.

How GLP-1 Medications Affect Nutrient Absorption

GLP-1 agonists reduce gastric acid secretion and slow stomach-to-intestine transit time, both critical for mineral solubilization and nutrient uptake. Additionally, reduced food volume decreases overall micronutrient intake, compounding absorption challenges even when intake quality remains high.

Patients on extended GLP-1 therapy often show declining serum B12, folate, and calcium levels by month 6-9. Intrinsic factor production may also be suppressed, mimicking pernicious anemia patterns. Early supplementation intervention—guided by baseline labs—prevents symptomatic deficiency and preserves bone density and neurological function.

Evidence-Based Nutrient Supplementation During GLP-1 Therapy

Below is a framework of clinically relevant supplements, their evidence strength, and typical dosing considerations during GLP-1 use. These recommendations should always be reviewed with a qualified healthcare provider before initiating any supplementation protocol.

Nutrient	Evidence & Clinical Context	Typical Support Range	Monitoring Consideration
Vitamin B12	Absorption risk highest; intrinsic factor suppression documented; 2-4x higher deficiency incidence	500 mcg–1000 mcg daily or 2000 mcg weekly	Serum B12, methylmalonic acid (MMA), homocysteine q6–12mo
Vitamin D	Reduced intestinal calcium-phosphate absorption; bone density loss risk in GLP-1 users	1000–2000 IU daily or 50,000 IU monthly	25-OH vitamin D level target >30 ng/mL; assess annually
Calcium	Malabsorption via reduced acid production; bone turnover risk; must separate from B12 supplements	500–1000 mg daily (citrate form preferred)	Serum calcium, alkaline phosphatase, DEXA screening if >50yo
Iron	Reduced gastric acid decreases non-heme iron solubility; phlebotomy baseline recommended	18–25 mg elemental iron (if deficient); alternate-day dosing	Serum ferritin, TIBC, hemoglobin q3–6mo; GI tolerance monitoring
Electrolytes (Sodium/Potassium)	Nausea, vomiting, and reduced intake increase hyponatremia and hypokalemia risk	Individualized; typically monitor via labs rather than blanket supplementation	Serum sodium, potassium, magnesium baseline and q3mo during therapy

Critical Medication-Supplement Interactions During GLP-1 Use

Certain supplements can reduce GLP-1 efficacy or increase gastrointestinal side effects. High-dose fiber taken concurrently with GLP-1 may worsen nausea and constipation; timing separation (2–4 hours) is recommended. Calcium citrate and iron supplements must be spaced apart due to chelation interference.

Patients combining GLP-1 with metformin or thiazolidinediones are at higher risk for B12 depletion and may benefit from proactive supplementation rather than waiting for symptomatic deficiency. Providers should document baseline micronutrient status before initiating dual therapy to establish personalized supplementation baselines.

Biomarker-Guided Supplementation: When to Personalize Your Protocol

Blanket supplementation recommendations ignore individual absorption capacity and genetic predisposition to nutrient deficiency. Pre-treatment biomarker panels measuring serum B12, folate, vitamin D, iron stores, and electrolytes enable targeted supplementation based on baseline risk rather than reactive dosing after deficiency develops.

Genetic factors in nutrient metabolism, assessed via pathways like FTO and MC4R variants, may influence both GLP-1 response and nutrient absorption efficiency. Providers using comprehensive biomarker data alongside genetic context can design supplementation protocols that align with individual metabolic patterns, increasing compliance and clinical outcomes.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context around nutrient metabolism pathways relevant to GLP-1 therapy. Variants in genes like FTO and MC4R can inform how your body processes certain micronutrients and may influence absorption efficiency during appetite-suppressed states. This information should be interpreted with a qualified healthcare provider to guide supplementation strategy.

The genetic test reveals predispositions in peptide-related pathways that can support more informed discussions about individual nutrient needs during GLP-1 treatment. However, genetic data does not predict exact supplementation requirements or GLP-1 response; it provides a foundation for personalized provider conversations rather than standalone decision-making.

By combining Precision Peptide Genetic Test insights with baseline biomarker assessment, patients and providers can develop tailored supplementation protocols that account for both genetic predisposition and current nutrient status, moving beyond population-average recommendations to precision wellness aligned with individual GLP-1 therapy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

GLP-1 Supplements & Nutrient Support | PlexusDx